• Mashup Score: 8
    • Log in to Twitter to see the latest. Join the conversation, follow accounts, see your Home Timeline, and catch up on Tweets from the people you know.

      Read the original tweet here

    Tweet Tweets with this article
    • RT @CardioNerdsJC: Don’t miss @Dr_DanMD's quick tutorial video on how to use https://t.co/LLOUCLgzUC to optimize your #CardsJC experience!…

    • RT @CardioNerdsJC: Don’t miss @Dr_DanMD's quick tutorial video on how to use https://t.co/LLOUCLgzUC to optimize your #CardsJC experience!…

    • Don’t miss @Dr_DanMD's quick tutorial video on how to use https://t.co/LLOUCLgzUC to optimize your #CardsJC experience! https://t.co/JWVJF7ZpIH

  • Mashup Score: 0
    • A powerful, real-time tool for people who live on Twitter.Monitor multiple timelines on a single screen. Track and organize content, and engage with your communities in real-time.Looking for the legacy version of TweetDeck? Go to legacy TweetDeck

      Read the original tweet here

    Tweet Tweets with this article
    • To enhance your #CardsJC experience, @Dr_DanMD created a quick tutorial video on how to optimize https://t.co/LLOUCLh7Ka to best enjoy the journal club. Check it out! 📽️ https://t.co/oZUtufnsTZ

  • Mashup Score: 3

    This randomized crossover trial assessed if implanting and programming a pacemaker for rate-adaptive atrial pacing improved exercise performance in patients with heart failure with preserved ejection fraction and chronotropic incompetence at a single US tertiary referral center.

    Tweet Tweets with this article
    • ATTENTION @CardioNerds🫀🤓 ⏱️#CardsJC starts in 1 hour! #HouseThomas will discuss RAPID-HF, which explored the effect of rate-adaptive atrial pacing on exercise performance in HFpEF w/ chronotropic incompetence. 👀 Check out the abstract here! https://t.co/eCp9CcZcFQ

  • Mashup Score: 0

    In the past decade, there have been major advances in lipid-lowering therapeutics, and another was made apparent in March at the American College of Cardiology Scientific Session. In addition to statins, available lipid-lowering therapies currently include ezetimibe, PCSK9 inhibitors, a small interfering RNA approach against PCSK9, angiopoietin-like protein 3 (ANGPTL3) inhibitors, and now

    Tweet Tweets with this article
    • For more learning on bempedoic acid and the CLEAR Outcomes trial following tonight's #CardsJC, check out this insightful Cardiology Today article led by @MichaelGoetsch, Hopkins Cardiology Fellow and incoming @OslerResidency ACS of the Barker Firm. https://t.co/EEa0pk4T25